1. Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013;41(2):445–56.
2. Merck & Co Inc. STEGLATRO™ (ertugliflozin) tablets, for oral use: prescribing information. 2017.
http://www.merck.com/
. Accessed 9 Feb 2018.
3. European Medicines Agency. CHMP summary of opinion: Steglatro (ertugliflozin). 2018.
http://www.ema.europa.eu/
. Accessed 9 Feb 2018
4. Merck & Co Inc. SEGLUROMET™ (ertugliflozin and metformin hydrochloride) tablets, for oral use: prescribing Information. 2017.
http://www.accessdata.fda.gov/
. Accessed 9 Feb 2018.
5. Merck & Co Inc. STEGLUJAN™ (ertugliflozin and sitagliptin) tablets, for oral use: prescribing Information. 2017.
http://www.accessdata.fda.gov/
. Accessed 9 Feb 2018.